Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation
AssigneeTiara Pharmaceuticals ,Inc.
InventorsYadon Arad, Liang C. Dong
Life of this patent
Estimating the term…
Abstract
The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.
Claims43
A composition in an oral dosage form comprising a sustained release (SR) component, wherein the SR component comprises ethyl ester of N-acetylcysteine, or a salt or solvate thereof;
- further comprising an immediate release (IR) component, wherein the IR component comprises an ethyl ester of N-acetylclysteine or a salt or solvate thereof;
- and
- wherein the composition, upon oral administration, provides a therapeutically effective plasma concentration of N-acetylcysteine over more than about 2 hours following the administration.
A composition in an oral dosage form comprising a sustained release (SR) component, wherein the SR component comprises
- ethyl ester of N-acetylcysteine, or a salt or solvate thereof;
- and
- a release rate controlling polymer.
Dependencies are inferred from the claim text.